secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-09-09T13:00:19+00:00
Accession:  0001104659-26-106156
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports preclinical DA-1726 tissue distribution: highest in adipose, prolonged retention
--------------------------------------------------------------------------------

- Preclinical study shows DA-1726-derived radioactivity highest in adipose tissue, with broad distribution and prolonged retention through 144h.
- Tissue-to-plasma ratios increased over time; greatest exposure in abdominal, subcutaneous, brown fat, and liver; minimal CNS penetration.
- CEO cites Phase 1 data: 48 mg dose achieved mean 9.8 cm waist circumference reduction after 8 weeks (Day 54).
- Company expects 16-week topline data in Q4 2026 and 24-week topline results in Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/0001104659-26-106156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/mtva-20260909x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-106156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer